Justin B. Klee, Co-Chief Executive Officer and Director of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX), filed a Form 4 on November 12, 2026, reporting the sale of 100,000 shares of common stock on November 9, 2026, pursuant to a Rule 10b5-1 trading plan.
Key Highlights
- Two sale transactions: Klee disposed of 37,483 shares at a weighted average price of $29.3917 and 62,517 shares at a weighted average price of $30.1062, both on November 9, 2026.
- Total shares sold: 100,000 shares of common stock were disposed of across the two transactions, according to the filing.
- Price ranges: The first tranche was sold in multiple transactions ranging from $28.72 to $29.71; the second tranche ranged from $29.72 to $30.29.
- Remaining ownership: Following the reported transactions, Klee directly beneficially owned 3,513,056 shares of common stock, the filing disclosed.
- 10b5-1 plan: The sales were effected pursuant to a Rule 10b5-1 trading plan adopted on May 11, 2026, according to the filing's explanation of responses.
Klee's November 2026 Share Dispositions Under Pre-Established Trading Plan
According to the Form 4 filed with the SEC on November 12, 2026, Justin B. Klee, who serves as Co-Chief Executive Officer and Director of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX), reported two separate dispositions of common stock on November 9, 2026. The filing indicates both transactions were carried out under a Rule 10b5-1 trading plan that Klee adopted on May 11, 2026.
In the first transaction, the filing reports that 37,483 shares were sold at a weighted average price of $29.3917, with individual sale prices ranging from $28.72 to $29.71. In the second transaction, 62,517 shares were sold at a weighted average price of $30.1062, with individual sale prices ranging from $29.72 to $30.29. The filing notes that full information on the number of shares sold at each separate price is available to the SEC staff upon request.
Prior to the reported transactions, Klee's direct beneficial ownership stood at 3,575,573 shares, as indicated by the first transaction row. After both dispositions were completed, his directly held beneficial ownership totaled 3,513,056 shares, the filing disclosed. No derivative securities transactions were reported. The Form 4 was signed by Joshua B. Cohen as Attorney in Fact on November 12, 2026.
What Was Disclosed
Amylyx Pharmaceuticals Co-CEO Justin B. Klee reported the sale of 100,000 shares of common stock on November 9, 2026, in two tranches under a pre-established Rule 10b5-1 plan, leaving him with direct beneficial ownership of 3,513,056 shares.




Please wait processing your request...